ASTELLAS PHARMA
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 2005-01-01
- Employees
- -
- Market Cap
- $22.5B
- Website
- https://www.astellas.com/
A Comparison Study Between Protopic (Tacrolimus) Ointment and Elidel (Pimecrolimus) Cream in Treating Subjects With Atopic Dermatitis
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-04-24
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 413
- Registration Number
- NCT00666302
Trial of Two Dosing Regimens of Micafungin Versus Caspofungin for the Treatment of Esophageal Candidiasis
- First Posted Date
- 2008-04-24
- Last Posted Date
- 2014-08-20
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 454
- Registration Number
- NCT00665639
- Locations
- 🇧🇷
7 Sites, Sao Paulo, Brazil
🇧🇷3 Sites, Belo Horizonte, Brazil
🇦🇷5 Sites, Buenos Aires, Argentina
A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
- First Posted Date
- 2008-04-21
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 2149
- Registration Number
- NCT00662909
A Placebo-controlled Study With an Extension Examining the Safety and Efficacy of Alefacept in Psoriatic Arthritis
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-04-16
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 185
- Registration Number
- NCT00659412
Assess the Efficacy and Safety of Alefacept With Narrow Band Ultraviolet B Phototherapy (nbUVB) vs. Alefacept Alone in Chronic Plaque Psoriasis Subjects
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-04-15
- Last Posted Date
- 2013-01-08
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 98
- Registration Number
- NCT00658606
A Study of Pharmacokinetics and Safety of Alefacept in Caucasian and Japanese Healthy Volunteers
- First Posted Date
- 2008-04-07
- Last Posted Date
- 2013-02-28
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 75
- Registration Number
- NCT00653822
Zolpidem (Myslee) Post Marketing Study in Adolescent Patients With Insomnia - Evaluation With Polysomnography
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-04-07
- Last Posted Date
- 2017-02-17
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 11
- Registration Number
- NCT00653562
A Study to Compare Early Steroid Withdrawal and Long-Term Steroid Maintenance Therapy in Kidney Transplant Patients
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2011-11-17
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 397
- Registration Number
- NCT00650468
Tacrolimus (FK506) P-III, Open-label Study in Refractory Ulcerative Colitis Patients
- First Posted Date
- 2008-03-26
- Last Posted Date
- 2014-08-26
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 32
- Registration Number
- NCT00643071
Tacrolimus as Secondary Intervention vs. Continuation of Cyclosporine in Renal Transplant Patients With Chronic Renal Allograft Failure (CRAF)
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-03-17
- Last Posted Date
- 2017-02-16
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 107
- Registration Number
- NCT00637143
© Copyright 2024. All Rights Reserved by MedPath